Amplified Sciences raises Seed+ round backed by AGA's GI Opportunity Fund
What's the deal? Amplified SciencesDealroom has a profile for this one. Try Dealroom →, a clinical-stage diagnostics company, has closed a Seed+ financing round backed by the American Gastroenterological AssociationDealroom has a profile for this one. Try Dealroom →'s (AGA) GI Opportunity Fund. Existing investor OCA VenturesDealroom has a profile for this one. Try Dealroom → led the round, with additional institutional investors participating.
The funds will go toward completing a pivotal real-world observational study for the company's lead product, PanCystPro — a diagnostic assay designed to help clinicians distinguish high-risk pancreatic cysts from benign ones. Amplified Sciences also plans to expand commercial partnerships, validate additional tests in its CLIA-CAP-accredited lab, and broaden market access.
Why now? Pancreatic cysts are showing up far more often in clinical practice thanks to widespread use of high-resolution imaging. Prevalence estimates have risen significantly over the past two decades.
Most cysts are benign, but a subset can become pancreatic ductal adenocarcinoma — one of the deadliest cancers. Current diagnostics often lack the accuracy to guide treatment decisions confidently, leading to unnecessary surgeries or drawn-out surveillance programmes.
"As detection of pancreatic cysts continues to rise, the call for accurate, low-sample-volume diagnostics becomes increasingly urgent," said Jo Davisson, chief scientific officer of Amplified Sciences.
What could go wrong? Amplified Sciences still needs to prove PanCystPro's clinical utility through its planned observational study. Diagnostics companies face a long road from study results to regulatory clearance, payer coverage, and widespread clinical adoption. The company did not disclose the size of the round, making it hard to assess how far the capital will stretch.
The signal: Amplified Sciences is tagged as "early growth" on Dealroom, suggesting this Seed+ round is bridging the company toward a commercial inflection point rather than funding pure R&D. The involvement of the AGA's dedicated GI Opportunity Fund — a specialist investment vehicle rather than a traditional VC — underscores that domain experts, not just financial backers, see multi-omic cyst diagnostics as a category worth building, particularly as early cancer detection draws increasing capital across the broader precision medicine landscape.
Read more: News-Medical
